Activation of inflammation and coagulation after infusion of C-reactive protein in humans.
C-reactive protein (CRP) has been postulated to play a causal part in atherosclerosis and its acute complications. We assessed the effects of CRP-infusion on coagulation and inflammatory pathways to determine its role in atherothrombotic disease. Seven male volunteers received an infusion on two occasions, containing 1.25 mg/kg recombinant human CRP (rhCRP) or diluent, respectively. CRP-concentrations rose after rhCRP-infusion from 1.9 (0.3 to 8.5) to 23.9 (20.5 to 28.1) mg/L, and subsequently both inflammation and coagulation were activated. This sequence of events suggests that CRP is not only a well known marker of cardiovascular disease, but is also probably a mediator of atherothrombotic disease.
Bisoendial
Radjesh J
RJ
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Kastelein
John J P
JJ
Levels
Johannes H M
JH
Zwaginga
Jaap J
JJ
van den Bogaard
Bas
B
Reitsma
Pieter H
PH
Meijers
Joost C M
JC
Hartman
Daniel
D
Levi
Marcel
M
Stroes
Erik S G
ES
D000328:Adult; D001161:Arteriosclerosis / Q000209:etiology*; D001777:Blood Coagulation / Q000187:drug effects*; D002097:C-Reactive Protein / Q000032:analysis / Q000633:toxicity*; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D007249:Inflammation / Q000139:chemically induced*; D015850:Interleukin-6 / Q000097:blood; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011994:Recombinant Proteins / Q000633:toxicity
D005338:Fibrin Fibrinogen Degradation Products; D015850:Interleukin-6; D008070:Lipopolysaccharides; D017395:Plasminogen Activator Inhibitor 1; D011994:Recombinant Proteins; C036309:fibrin fragment D; D002097:C-Reactive Protein